Double impact on p-glycoprotein by statins enhances doxorubicin cytotoxicity in human neuroblastoma cells

International Journal of Cancer

Volumn 126, Issue 9, 2010, Pages 2025-2035

  Sieczkowski, Evelyn ^a   Lehner, Claudia ^a   Ambros, Peter F ^b   Hohenegger, Martin ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b CHILDREN'S CANCER RESEARCH INSTITUTE   (Austria)

Author keywords

ATPbinding cassette transporter; Glycosylation; HMG CoA reductase inhibitors; Neuroblastoma; P glycoprotein

Indexed keywords

ABC TRANSPORTER; ANTHRACYCLINE; ATORVASTATIN; DOXORUBICIN; DYE; GLYCOPROTEIN P; GLYCOSIDASE; GLYCOSYLATED PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MULTIDRUG RESISTANCE PROTEIN 1; N GLYCOSIDASE F; ONCOPROTEIN; PROTEIN MYCN; SIMVASTATIN; UNCLASSIFIED DRUG; VERAPAMIL;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG INHIBITION; GENE AMPLIFICATION; GLYCOSYLATION; HUMAN; HUMAN CELL; INTRACELLULAR MEMBRANE; NEUROBLASTOMA CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TRANSPORT; REAL TIME POLYMERASE CHAIN REACTION; DRUG ANTAGONISM; DRUG RESISTANCE; METABOLISM; MULTIDRUG RESISTANCE; NEUROBLASTOMA; PATHOLOGY; TUMOR CELL LINE;

ATP-BINDING CASSETTE TRANSPORTERS; CELL LINE, TUMOR; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; GLYCOSYLATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NEUROBLASTOMA; P-GLYCOPROTEIN; SIMVASTATIN;

EID: 77949877479     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24885     Document Type: Article

References (39)

1. Schwab M, Westermann F, Hero B, Berthold F. Neuroblastoma: biology and molecular and chromosomal pathology. Lancet Oncol 2003;4:472-480 (Pubitemid 37009955)
2. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 1984;224:1121-1124
3. Seeger RC, Brodeur GM, Sather H, Dalton A, Siegel SE, Wong KY, Hammond DN. Association of multiple copies of the N-myc oncogene with rapid disease progression of neuroblastomas. N Engl J Med 1985; 313:1111-1116
4. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003;3:203-216
5. Norris MD, Bordow SB, Marshall GM, Haber PS, Cohn SL, Haber M. Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma. N Engl J Med 1996; 334: 231-238
6. Matsunaga T, Shirasawa H, Hishiki T, Enomoto H, Kouchi K, Ohtsuka Y, Iwai J, Yoshida H, Tanabe M, Kobayashi S, Asano T, Etoh T, et al. Expression of MRP and cMOAT in childhood neuroblastomas and malignant liver tumors and its relevance to clinical behaviour. Jpn J Cancer Res 1998; 89:1276-1283
7. Haber M, Smith J, Bordow SB, Flemming C, Cohn SL, London WB, Marshall GM, Norris MD. Association of high-level MRP1 expression with poor clinical outcome in a large prospective study of primary neuroblastoma. J Clin Oncol 2006; 24:1546-1553
8. Borst P, Elferink RO. Mammalian ABC transporters in health and disease. Annu Rev Biochem 2002;71:537-592
9. Dean M, Rzhetsky A, Allikmets R. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res 2002; 117:1156-1166
10. Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, Pastan I. Expression of a multidrug resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 1987;84:265-269 (Pubitemid 17013615)
11. Norris MD, Bordow SB, Haber PS, Marshall GM, Kavallaris M, Madafiglio J, Cohn SL, Salwen H, Schmidt ML, Hipfner DR, Cole SP, Deeley RG, et al. Evidence that the MYCN oncogene regulates MRP gene expression in neuroblastoma. Eur J Cancer 1997;33:1911-1916
12. Blanc E, Goldschneider D, Ferrandis E, Barrois M, lle Le Roux G, Leonce S, Douc-Rasy S, Benard J, Raguenez G. MYCN enhances P-gp/MDR1 gene expression in the human metastatic neuroblastoma IGR-N-91 model. Am J Pathol 2003;163: 321-331
13. Nakagawara A, Kadomatsu K, Sato S, Kohno K, Takano H, Kuwano M. Inverse expression of MYCN and mdr-1 in human neuroblastoma. Prog Clin Biol Res 1991; 366:11-19.
14. Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006;5:219-234
15. Gillet JP, Efferth T, Remacle J. Chemotherapy-induced resistance by ATP-binding cassette transporter genes. Biochim Biophys Acta 2007; 1775:237-262
16. Levine GN, Keaney JF, Vita JA. Cholesterol reduction in cardiovascular disease: clinical benefits and possible mechanisms. N Engl J Med 1995;332:512-521
17. Kashani A, Phillips CO, Foody JM, Wang Y, Mangalmurti S, Ko DT, Krumholz HM. Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation 2006;114:2788-2797
18. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990;343: 425-430
19. Harwood HJ, Jr, Alvarez IM, Noyes WD, Stacpoole PW. In vivo regulation of human leukocyte 3-hydroxy-3methylglutaryl coenzyme A reductase: increased enzyme protein concentration and catalytic efficiency in human leukaemia and lymphoma. J Lipid Res 1991;32: 1237-1252
20. Dimitroulakos J, Ye LY, Benzaquen M, Moore MJ, Kamel-Reid S, Freedman MH, Yeger H, Penn LZ. Differential sensitivity of various pediatric cancers and squamous cell carcinomas to lovastatin induces apoptosis: therapeutic implications. Clin Cancer Res 2001;7:158-167
21. Van de Donk NW, Kamphuis MM, Lokhorst HM, Bloem AC. The cholesterol lowering drug lovastatin induces cell death in myeloma plasma cells. Leukemia 2002; 16:1362-1371
22. Werner M, Sacher J, Hohenegger M. Mutual amplification of apoptosis by statin-induced mitochondrial stress and doxorubicin toxicity in human rhabdomyosarcoma cells. Br J Pharmacol 2004;143:715-724
23. Bogman K, Peyer AK, Török M, Küsters E, Drewe J. HMG-CoA reductase inhibitors and P-glycoprotein modulation. Br J Pharmacol 2001;132:1183-1192
24. Wang E, Casciano CN, Clement RP, Johnson WW. HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein. Pharm Res 2001;18:800-806
25. Ambros IM, Rumpler S, Luegmayr A, Hattinger CM, Strehl S, Kovar H, Gadner H, Ambros PF. Neuroblastoma cells can actively eliminate supernumerary MYCN gene copies by micronucleus formation\ sign of tumour cell revertance? Eur J Cancer 1997;33:2043-2049
26. Holló Z, Homolya L, Davis CW, Sarkadi B. Calcein accumulation as a fluorometric functional assay of the multidrug transporter. Biochim Biophys Acta 1994; 1191:384-388
27. Bradford M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-254
28. Pietrzaka M, Wieczoreka Z, Stachelska A, Darzynkiewicz Z. Interactions of chlorophyllin with acridine orange, quinacrine mustard and doxorubicin analyzed by light absorption and fluorescence spectroscopy. Biophys Chem 2003;104:305-313
29. Sacher J, Weigl L, Werner M, Szegedi C, Hohenegger M. Delineation of myotoxicity induced by 3-hydroxy-3-methylglutaryl CoA reductase inhibitors in human skeletal muscle cells. J Pharmacol Exp Ther 2004; 314:1032-1041
30. Girgert R, Vogt Y, Becke D, Bruchelt G, Schweizer P. Growth inhibition of neuroblastoma cells by lovastatin and L-ascorbic acid is based on different mechanisms. Cancer Lett 1999;137:167-172
31. Connelly-Smith L, Pattinson J, Grundy M, Shang S, Seedhouse C, Russell N, Pallis M. P-glycoprotein is downregulated in KG1a-primitive leukemia cells by LDL cholesterol deprivation and by HMG-CoA reductase inhibitors. Exp Hematol 2007;35:1793-1800
32. Schinkel AH, Kemp S, Dollé M, Rudenko G, Wagenaar E. N-Glycosylation and deletion mutants of the human MDR1 P-glycoprotein. J Biol Chem 1993;268: 7474-7481
33. Wang Y, Loo TW, Bartlett MC, Clarke DM. Modulating the folding of P-glycoprotein and cystic fibrosis transmembrane conductance regulator truncation mutants with pharmacological chaperones. Mol Pharmacol 2007;71:751-758
34. Yoshimura A, Kuwazuru Y, Sumizawa T, Ikeda S, Ichikawa M, Usagawa T, Akiyama S. Biosynthesis, processing and half-life of P-glycoprotein in a human multidrug-resistant KB cell. Biochim Biophys Acta 1989;992:307-314
35. Loo TW, Clarke DM. Superfolding of the partially unfolded core-glycosylated intermediate of human P-glycoprotein into the mature enzyme is promoted by substrate-induced transmembrane domain interactions. J Biol Chem 1998;273: 14671-14674
36. Sanyal S, Frank CG, Menon AK. Distinct flippases translocate glycerophospholipids and oligosaccharide diphosphate dolichols across the endoplasmic reticulum. Biochemistry 2008;47:7937-7946
37. Bentley J, Quinn DM, Pitman RS, Warr JR, Kellett GL. The human KB multidrug-resistant cell line KB-Cl is hypersensitive to inhibitors of glycosylation. Cancer Lett 1997;115:221-227
38. Loo TW, Clarke DM. The human multidrug resistance P-glycoprotein is inactive when its maturation is inhibited: potential for a role in cancer chemotherapy. FASEB J 1999;13:1724-1730
39. Hall MD, Okabe M, Shen DW, Liang XJ, Gottesman MM. The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy. Annu Rev Pharmacol Toxicol 2008;48: 495-535.